Literature DB >> 12656644

Pharmacological treatment of patients with peripheral arterial disease.

Chin K Kim1, Carsten M Schmalfuss, Richard S Schofield, David S Sheps.   

Abstract

Atherosclerosis is a disease process that affects the coronary, cerebral and peripheral arterial circulation. While great emphasis has been placed on the aggressive pharmacological management of coronary artery disease, less attention has been paid to the pharmacological management of peripheral vascular disease, despite its significant morbidity and mortality. The purpose of medical management in peripheral arterial disease is to relieve symptoms of claudication and to prevent thrombotic vascular events. These goals are best achieved through aggressive risk factor modification and pharmacotherapy. Risk factor modification includes smoking cessation, adequate control of blood pressure and cholesterol, as well as aggressive glycaemic control in patients with diabetes mellitus. Antiplatelet therapy and relief of claudication is also achieved through pharmacotherapy. With aggressive risk factor modification and adequate pharmacotherapy, patients with peripheral arterial disease can have an improved quality of life as well as prolonged survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12656644     DOI: 10.2165/00003495-200363070-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  82 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Thrombolysis in the management of lower limb peripheral arterial occlusion--a consensus document. Working Party on Thrombolysis in the Management of Limb Ischemia.

Authors: 
Journal:  Am J Cardiol       Date:  1998-01-15       Impact factor: 2.778

Review 3.  Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-15

4.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

5.  Peripheral arterial disease detection, awareness, and treatment in primary care.

Authors:  A T Hirsch; M H Criqui; D Treat-Jacobson; J G Regensteiner; M A Creager; J W Olin; S H Krook; D B Hunninghake; A J Comerota; M E Walsh; M M McDermott; W R Hiatt
Journal:  JAMA       Date:  2001-09-19       Impact factor: 56.272

6.  The demographics of claudication and the aging of the American population.

Authors:  W B Kannel
Journal:  Vasc Med       Date:  1996       Impact factor: 3.239

7.  Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells.

Authors:  T Igawa; T Tani; T Chijiwa; T Shiragiku; S Shimidzu; K Kawamura; S Kato; F Unemi; Y Kimura
Journal:  Thromb Res       Date:  1990-02-15       Impact factor: 3.944

8.  Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment.

Authors:  M M McDermott; P Greenland; K Liu; J M Guralnik; M H Criqui; N C Dolan; C Chan; L Celic; W H Pearce; J R Schneider; L Sharma; E Clark; D Gibson; G J Martin
Journal:  JAMA       Date:  2001-10-03       Impact factor: 56.272

9.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

10.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

View more
  2 in total

1.  Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction.

Authors:  Eric P Davidson; Lawrence J Coppey; Nigel A Calcutt; Christine L Oltman; Mark A Yorek
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

2.  Patient education interventions to improve physical activity in patients with intermittent claudication: a protocol for a systematic mixed-studies review.

Authors:  Ukachukwu Okoroafor Abaraogu; Philippa Margaret Dall; Christopher Andrew Seenan
Journal:  BMJ Open       Date:  2016-05-20       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.